Option chain shows key data for Kyowa Kirin's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Kyowa Kirin.

Kyowa Kirin (OTC:KYKOF) Stock, Option Chain

Kyowa Kirin Co Ltd is a drug manufacturing company that focuses on biologic medicines. Its operations emphasize four categories: nephrology, oncology, immunology and allergy, and the central nervous system. The company has two reportable segments, Pharmaceuticals and Biochemicals. The pharmaceuticals business manufactures and sells ethical pharmaceuticals, diagnostic reagents, and other products. The biochemicals business manufactures and sells raw materials for pharmaceutical and industrial use, mainly amino acids, nucleic acids and related compounds, healthcare products, and others.

Biotech

News

Penny Stocks

Previews

Small Cap

Trading Ideas

ABBV

ADMP

AGIO

ALKS

ALXN

APTO

AUTL

BGNE

BIIB

BLUE

CGEN

CHRS

CNST

CRIS

CRSP

CYAD

ELDN

FBIO

FMTX

GOSS

IMRA

IOVA

KDNY

KYKOF

LMNL

MBIO

MEIP

Morgan Stanley Capital Protected Notes for S&P 500 Index

NEXI

ONCT

PDSB

PGEN

PTGX

SCYX

VERA

VRTX

XFOR

Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week, headlining the biotech news flow of the week.

The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck

Health Care

Contracts

General

CERC

Cerecor Inc&#39;s (NASDAQ: CERC) wholly-owned subsidiary, Aevi Genomic Medicine LLC, has 

Cerecor Inks New Global License Agreement With Kyowa Kirin For CERC-002

Long Ideas

ARDX

IRWD

Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day

KYOWA HAKKO KOGYO by Kyowa Hakko Kogyo Co., Ltd.

Kyowa Kirin Co Ltd

Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi raised $126.8 million in a Hong Kong IPO.

Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare

Kyowa Kirin Co (JP:4151) has released an update. Kyowa Kirin Co., Ltd. has been actively purchasing its own shares, buying back 1,205,700 shares fo...

Kyowa Kirin Advances Share Buyback Program

Kyowa Kirin Co., Ltd. 2024 Q2 - Results - Earnings Call Presentation

Kyowa Kirin Non-GAAP EPS of ¥70.75, revenue of ¥232.9B

Ardelyx's ($ARDX) strides in the internal medicine sector have put it on a promising growth trajectory. The company has experienced solid growth an...

Ardelyx (ARDX) Beats Expectations in Q2 and Offers Promising Outlook

BridgeBio Pharma ($BBIO) is capturing attention with its unique approach to developing gene-based therapies for cancer and genetic-driven ailments....

A Promising Pipeline Ready to Breakout at BridgeBio Pharma (BBIO)

A Promising Pipeline Ready to Break out at BridgeBio Pharma (BBIO)

Kyowa Kirin 9M GAAP EPS of Yen 105.19, revenue of Yen 362.8B

Scotiabank lowered the firm's price target on Kura Oncology (KURA) to $18 from $22 and keeps a Sector Perform rating on the shares. The firm adjust...

Kura Oncology price target lowered to $18 from $22 at Scotiabank

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Nvidia (NVDA) reported Q3 results that...

Comments

Kyowa Kirin

Kyowa Kirin (KYKOF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga